<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="146665">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01191177</url>
  </required_header>
  <id_info>
    <org_study_id>09-02-0066</org_study_id>
    <nct_id>NCT01191177</nct_id>
  </id_info>
  <brief_title>Investigational Study of Oral Fish Oil in Treating Parenteral Nutrition Associated Liver Disease</brief_title>
  <official_title>An Initial Trial of Enteral Fish Oil Supplementation in the Treatment of Parenteral Nutrition-associated Liver Disease in Patients With Short Bowel Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Children’s Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Harvard University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston Children’s Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the usefulness of oral fish oil(Lovaza)in
      normalizing liver function in patients who have parenteral nutrition associated liver
      disease. The investigators believe that patients who take oral fish oil will normalize liver
      function faster than those who do not
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">January 2012</completion_date>
  <primary_completion_date type="Anticipated">January 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Normalization of ALT</measure>
    <description>The primary aim is to examine the efficacy of Lovaza, when compared to placebo, on normalizing liver function, as measured primarily by amino alanine transferase (ALT). The investigators believe that patients in the Lovaza group will normalize ALT faster than in the placebo group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Normalization other liver function tests and inflammatory status</measure>
    <description>The investigators believe that Lovaza will result in faster reduction of the serum levels of the following markers: total bilirubin, aspartate amino transferase (AST), alkaline phosphatase, gamma glutamyl transpeptidase (GGTP) &amp; C-reactive protein (CRP).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Liver Disease</condition>
  <condition>Short Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Lovaza group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to this group will receive Lovaza 1gram per kilogram of body weight, not exceeding 4grams a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients randomized to this group will receive corn oil supplement 1gram per kilogram of body weight, not exceeding 4grams per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lovaza (omega-3-acid ethyl ester)</intervention_name>
    <description>supplied as 1gram transparent soft-gelatin capsules filled with yellow oil, dosage is 1gram per kilogram of body weight per day, not exceeding 4grams per day until normalization of liver function test</description>
    <arm_group_label>Lovaza group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>corn oil</intervention_name>
    <description>supplied as 1gram transparent soft gelatin capsules filled with yellow oil, dosage is 1gram per kilogram of body weight per day, not exceeding 4gram a day</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of parenteral nutrition(PN)administration &gt;4weeks

          -  PN associated liver disease from intestinal failure

          -  ability to take full enteral feed

          -  body weight equal or greater than 3kg

          -  elevated ALT level twice of that normal(ALT&gt;84)at the time PN is weaned off

        Exclusion Criteria:

          -  Hemodynamic instability

          -  renal failure

          -  suspected congenital obstruction of the hepatobiliary system

          -  diagnosis hepatitis A, B, or C

          -  diagnosis of alpha 1-antitrypsin deficiency

          -  diagnosis of cytomegalovirus infection

          -  diagnosis of HIV

          -  children in care
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tom Jaksic, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hopsital Boston</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tom Jaksic, MD, PhD</last_name>
    <phone>617 355 9600</phone>
    <email>tom.jaksic@childrens.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>KuangHorng(Jamie) Kang, MD</last_name>
    <phone>617 919 2969</phone>
    <email>kuanghorng.kang@childrens.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tom Jaksic, MD, PhD</last_name>
      <phone>617-355-9600</phone>
      <email>tom.jaksic@childrens.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>KuangHorng(Jamie) Kang, MD</last_name>
      <phone>617 919 2969</phone>
      <email>kuanghorng.kang@childrens.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Tom Jaksic, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <lastchanged_date>November 10, 2011</lastchanged_date>
  <firstreceived_date>August 27, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>oral fish oil</keyword>
  <keyword>Lovaza</keyword>
  <keyword>Omega-3-acid supplementation</keyword>
  <keyword>Faster normalization of ALT with oral fish oil</keyword>
  <keyword>Faster normalization of liver function test with oral fish oil</keyword>
  <keyword>Increased growth with oral fish oil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Short Bowel Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
